Last $31.22 USD
Change Today +0.47 / 1.53%
Volume 1.9M
AUXL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

auxilium pharmaceuticals inc (AUXL) Snapshot

Open
$31.06
Previous Close
$30.75
Day High
$31.57
Day Low
$30.93
52 Week High
10/9/14 - $33.00
52 Week Low
10/31/13 - $16.71
Market Cap
1.6B
Average Volume 10 Days
2.7M
EPS TTM
$-2.77
Shares Outstanding
50.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AUXILIUM PHARMACEUTICALS INC (AUXL)

auxilium pharmaceuticals inc (AUXL) Related Businessweek News

View More BusinessWeek News

auxilium pharmaceuticals inc (AUXL) Details

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, together with its subsidiaries, develops and markets pharmaceutical products for urology and sexual health worldwide. The company markets Testim, a testosterone gel for the topical treatment of hypogonadism; TESTOPEL, an implantable TRT product; Edex, a injectable drug for erectile dysfunction (ED); Osbon ErecAid, a device for treating ED; STENDRA, a line oral therapy for ED; Striant, a buccal system for testosterone delivery; and XIAFLEX for the treatment of Dupuytren's contracture in adults with a palpable cord, as well as for the treatment of Peyronie’s. It also markets Theo-24 for the treatment of COPD and asthma; and Semprex-D for the treatment of seasonal allergic rhinitis. In addition, the company is developing XIAFLEX, which is in Phase IIb clinical trial for the treatment of adhesive capsulitis, as well as in Phase IIa clinical trial for the treatment of edematous fibrosclerotic panniculopathy. Further, it is developing a high concentration testosterone gel product. The company sells its products to wholesale drug distributors, specialty pharmacies, specialty distributors, and chain drug stores. It has a development and license agreement with BioSpecifics Technologies Corp.; development, commercialization, and supply agreement with Pfizer, Inc.; collaboration agreement with the Swedish Orphan Biovitrum AB; development, commercialization, and supply agreement with Asahi Kasei Pharma Corporation; and collaboration agreement with Actelion Pharmaceuticals Ltd. The company was founded in 1999 and is headquartered in Chesterbrook, Pennsylvania.

635 Employees
Last Reported Date: 08/7/14
Founded in 1999

auxilium pharmaceuticals inc (AUXL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $666.2K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $437.1K
Chief Medical Officer
Total Annual Compensation: $394.7K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $363.9K
Compensation as of Fiscal Year 2013.

auxilium pharmaceuticals inc (AUXL) Key Developments

U.S. Food and Drug Administration Approves Auxilium Pharmaceuticals, Inc.'s Supplemental Biologics Application for XIAFLEX(R) (Collagenase Clostridium Histolyticum or CCH) for Treatment of Up to Two Dupuytren's Contracture Joints in the Same Hand During Single Treatment Visit

Auxilium Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved a supplemental Biologics Application (sBLA) for XIAFLEX(R) (collagenase clostridium histolyticum or CCH) for the treatment of up to two Dupuytren's contracture (DC) joints in the same hand during a single treatment visit. XIAFLEX is a biologic approved in the U.S., EU, Canada and Australia for the treatment of adult DC patients with a palpable cord. DC is a progressive hand disease that can present with multiple collagen cords that limit finger joint movement and result in 70,000 procedures to treat affected patients every year. It is estimated that 35 to 40% of annual U.S. surgical procedures to treat DC have been performed to treat at least two DC joints at a time. The sBLA was based on positive results from the global, multicenter Phase 3b MULTICORD (Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren's) trial, together with data from company's earlier studies (AUX-CC-861 and AUX-CC-864). The MULTICORD study also examined efficacy and safety of the finger extension procedure at 24, 48 or 72 hours post injection. In Phase 3b clinical trials, two concurrent XIAFLEX injections were safely used in the treatment of one hand with multiple affected joints. The company has also worked with the FDA to modify the XIAFLEX REMS to communicate a change to the wording of the contraindication in patients with a history of hypersensitivity to XIAFLEX or other collagenase and to add information related to the risk of skin lacerations in the treated finger or hand of patients with Dupuytren's contracture.

Auxilium Pharmaceuticals Inc., Endo International plc - M&A Call

To discuss the transactions between the two companies

Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data from Multicord and Retreatment Studies at The ASSH Annual Meeting

Auxilium Pharmaceuticals Inc. announced the first presentation of positive safety and efficacy data from the AUX-CC-867 MULTICORD (MULtiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytrens) Phase 3b study. This study evaluated collagenase clostridium histolyticum (CCH) for the treatment of two Dupuytren's cords concurrently in the same hand. In addition, the study examined expanded flexibility with timing of the finger extension procedure. Additional positive data were presented from the AUX-CC-862 retreatment study that evaluated the retreatment of recurrent contracture in joints that were previously treated with CCH. These data will be presented at the 69(th) Annual Meeting of the American Society for Surgery of the Hand (ASSH) being held in Boston, September 18-20, 2014. XIAFLEX(R) (CCH) is a biologic approved in the U.S., EU, Canada and Australia for the treatment of adult Dupuytren's contracture (DC) patients with a palpable cord. DC is a progressive hand disease that can present with multiple collagen "cords" that limit finger movement. It is estimated that 35% to 40% of annual surgical procedures in the U.S. are performed to treat more than one DC cord at a time.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AUXL:US $31.22 USD +0.47

AUXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acrux Ltd A$1.19 AUD +0.065
Actavis plc $237.21 USD +5.80
Antares Pharma Inc $2.01 USD +0.03
Endo International PLC $64.66 USD +1.47
Mylan Inc/PA $50.43 USD +0.07
View Industry Companies
 

Industry Analysis

AUXL

Industry Average

Valuation AUXL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.8x
Price/Book 8.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AUXILIUM PHARMACEUTICALS INC, please visit www.auxilium.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.